Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
Journal of the European Academy of Dermatology and Venereology | Nov 19, 2017
Kuo CM, et al. - The effects of tofacitinib were comprehensively investigated for the treatment of moderate-to-severe plaque psoriasis. In the cases where moderate-to-severe plaque psoriasis was unresponsive to other therapies and for patients exhibited intolerance to other therapies or for those who prefered oral medications, tofacitinib could serve as a therapeutic option.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
